TY  - JOUR
PY  - 2018//
TI  - Levodopa-carbidopa-entacapone overdose presenting as altered mental status, xanthoderma, and yellowish sclera
JO  - Signa Vitae
A1  - Lee, S.H.
A1  - Yun, S.J.
A1  - Ryu, S.
A1  - Choi, S.W.
A1  - Kim, H.J.
A1  - Kang, T.K.
A1  - Oh, S.C.
A1  - Cho, S.J.
SP  - 75
EP  - 77
VL  - 14
IS  - 2
N2  - Levodopa-carbidopa-entacapone is a single combination drug consisting of levodopa (aromatic amino acid), carbidopa (dopa-decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase inhibitor). The Food and Drug Administration approved levodopa-carbidopaentacapone in 2003, as treatment for idiopathic Parkinson's disease in patients experiencing signs and symptoms of wearing-off. Although various adverse drug reactions of levodopa-carbidopa-entacapone have been recorded, there has been no reported case of levodopa-carbidopa-entacapone overdose. We report the first case of signs and symptoms of an overdose of levodopa-carbidopa-entacapone (levodopa: 3000 mg; carbidopa: 750 mg; entacapone: 6000 mg) in a suicide attempt, presenting as altered mentality, xanthoderma, and yellowish sclera without hyperbilirubinemia. © 2018, Pharmamed Mado Ltd. All rights reserved.<p /> <p>Language: en</p>
LA  - en
SN  - 1334-5605
UR  - http://dx.doi.org/10.22514/SV142.102018.12
ID  - ref1
ER  -